TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01716520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol 62.5/25 mcg
Description: Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Umeclidinium 62.5 mcg
Description: Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vilanterol 25 mcg
Description: Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
Study: NCT00178646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Botox 75-150 units, single treatment only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Botox 75-150 units, single treatment only

Intervention type: DRUG
Group type: OTHER
Intervention: Botox
Description: Botox 75-150 units, single treatment only
Study: NCT02072070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C
Description: TissueGene-C at 1.8 x 10\^7 cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control(Normal Saline)
Study: NCT01603407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: daily prednisone (0.75 mg/kg/day) tablets for 36-60 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months
Study: NCT03376113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the volitional help sheet
Description: A sheet includes two columns: one shows critical situations that easily trigger self-harm; other one shows appropriate solutions for patients to prevent self-harm.
Study: NCT00822770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Dose of 40 mg/m\^2 beginning on Day -6 for four consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Dose of 130 mg/m\^2 for four consecutive days, immediately after completion of Fludarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Dose of 130 mg/m\^2 for four consecutive days, immediately after completion of Fludarabine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic blood stem cell transplant
Description: Stem Cell Infusion (Bone marrow or PBPC)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic blood stem cell transplant
Description: Stem Cell Infusion (Bone marrow or PBPC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG (Thymoglobulin)
Description: Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG (Thymoglobulin)
Description: Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
Study: NCT04647838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
Study: NCT01975298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Oral Administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: Interferon β1A 30 μg/0.5mL administered Intra Muscular
Study: NCT02917772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab/Ipilimumab
Description: * Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 8)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)
Study: NCT00790205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.
Study: NCT00508989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin-ER
Description: 500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Study: NCT01368471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGuard
Description: MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control BMS or DES
Description: Control BMS or DES
Study: NCT01932476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten Challenge
Description: Three-day gluten containing dietary challenge.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten Challenge
Description: Three-day gluten containing dietary challenge.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sham Challenge
Description: Three-day sham (gluten free) dietary challenge

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sham Challenge
Description: Three-day sham (gluten free) dietary challenge
Study: NCT03982212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copaxone
Description: * Agent: Glatiramer acetate (Copaxone®)~* Dose: 40 mg~* Route: Intratumoral injection~* Schedule: At least 1 dose, up to 3 doses, with each dose being at least 48 hours apart and last dose within 96 hours of standard of care surgery.
Study: NCT03998722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagivital
Description: Vagivital once Daily for 12 weeks
Study: NCT02016209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel
Description: Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
Study: NCT04484584

Intervention type: OTHER
Intervention: complex decongestive therapy
Description: Manual lymphatic drainage Manuel lymphatic drainage therapeutic technique is used for reducing edema and symptoms related with edema by accelerating lymphatic drainage. The aim of massage along the extremity is to provide fluid drainage.Manuel lymphatic drainage stimulates the internal contraction of lymphatic channels. If interstitial space concentration of protein is reduced, it provides drainage of obstructed lymph fluid from local lymph nodes.

Intervention type: OTHER
Intervention: complex decongestive therapy
Description: Manual lymphatic drainage Manuel lymphatic drainage therapeutic technique is used for reducing edema and symptoms related with edema by accelerating lymphatic drainage. The aim of massage along the extremity is to provide fluid drainage.Manuel lymphatic drainage stimulates the internal contraction of lymphatic channels. If interstitial space concentration of protein is reduced, it provides drainage of obstructed lymph fluid from local lymph nodes.
Study: NCT01355640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast-feeding
Description: Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Mothers breast-fed their babies. The study was initiated when the infants were observed to have a large amount of areola in their mouth, with flanged lips and active jaw movements. Then two minutes after the breast-feeding, an experienced technician began to do heel lance, heel lance was given by the same experienced technician.Mothers breast-fed their babies two minutes before, during and eight minutes after the heel lance. Throughout the whole procedure, mothers were encouraged to continue breast-feeding when the babies stopped sucking and/or began to cry.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-nutritive sucking
Description: Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Each mother in this group was given a vacuum pacifier( the brand is Goodbaby) to console her baby. Heel lance was given by the same experienced technician. The study was initiated when the infants can suck the pacifier and hold it by himself without others' help. This generally requires half or one minute. Then two minutes after non-nutritive sucking, an experienced technician began to do heel lance. Babies sucked the pacifier two minutes before, during and eight minutes after heel lance. Throughout the whole procedure, mothers were encouraged to continue non-nutritive sucking when the babies stopped sucking and/or began to cry.
Study: NCT00643617

Intervention type: RADIATION
Group type: OTHER
Intervention: CyberKnife Stereotactic Radiosurgery - Low Risk
Description: 38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 2 mm around the prostate

Intervention type: RADIATION
Group type: OTHER
Intervention: CyberKnife Stereotactic Radiosurgery - Intermediate Risk
Description: 38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 5mm posterolaterally
Study: NCT02119897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Light Therapy
Study: NCT01512797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin phosphate
Description: 100 mg/day orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Placebo Pill per day
Study: NCT03933462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnoSpire Go
Description: Participants will use for 30 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer
Description: Participants will use for 30 days.
Study: NCT02465736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/ m2 on days 1, 8, 15 and 22.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).
Study: NCT00150618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (1 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (2 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (3 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (4 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00382447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard nebulizer
Description: Standard small volume nebulizer for aerosolized medication delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: breath actuated nebulizer
Description: Nebulizer that dispenses medication only during the inspiratory phase
Study: NCT06202976

Intervention type: OTHER
Intervention: Secondary data collection
Description: clinical data
Study: NCT02813044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: total intravenous anesthesia (TIVA)
Description: In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhalation anesthesia group
Description: In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
Study: NCT00656045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
Study: NCT03267342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-one financial counseling
Description: Clients will be given access to one-on-one financial counseling, provided by trained peer specialists, initially working under the guidance of the project director. The Consumer Financial Protection Bureau's Your Money, Your Goals: Financial Empowerment Toolkit for Social Services Programs (21) will be used as a reference during counseling sessions, with a view to developing a manual based on clients' existing experiences and coping strategies, such that the desired behavior change is manageable, realistic, and based on real-life possibilities rather than idealized circumstances which may be far from the reality of people's lives. Counseling will in all cases be responsive to clients' particular needs and concerns, rather than following a predetermined sequence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support group
Description: Support groups, facilitated by peer specialists and guided initially by the project director, will be offered for clients interested in specific financial issues such as budgeting, managing benefits, wise spending, planning and saving. The peer support groups will focus on enabling clients to share their own experiences with finances.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported access to mainstream banking services
Description: Interested clients will be helped to open bank accounts at banks of their choice, and to manage associated tools such as Automatic Teller Machine (ATM) cards and online bill pay. Clients will also be advised regarding use of non-bank financial products such as prepaid cards and check cashers. Representatives from both bank and non-bank providers will be invited to come in and talk with clients about the services they offer, and clients will also be invited to visit the facilities to be guided around the available services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A matched savings account
Description: Clients will have the option of joining a savings club, which will combine group meetings, facilitated by a peer specialist under the initial guidance of the project director, and regular savings deposits towards specified goals. Clients will be offered a limited savings match as an incentive to achieve their savings goal (for example, the savings club will offer a 50% match on any money saved within a specified time period towards a specific goal, up to a maximum of a $100 match).
Study: NCT06484946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic occupational therapy
Description: Each week, the children participated in a 45-minute aquatic occupational therapy group that consisted of warmup on land, 30 mins of sensory activities in the water, and 10 mins of social activity in the water
Study: NCT04383756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Blood
Description: Up to 4 units (each unit contains 350mL) of leukoreduced donor whole blood

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Banked Blood
Description: Up to 350mL of Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets)
Study: NCT01373775

Intervention type: OTHER
Intervention: Patient charts reviewing
Description: Reviewing chart and identifying risk factors

Intervention type: OTHER
Intervention: Patient charts reviewing
Description: Reviewing chart and identifying risk factors
Study: NCT00656045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The Physical Activity arm will receive an activity goal (200 minutes/week of moderate-intense physical activity).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV Watching
Description: The TV Watching arm will receive a TV watching goal of watching less than 10 hours of TV/week.
Study: NCT01081886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade 4.0
Description: The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
Study: NCT03106090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational materials
Description: The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns. They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
Study: NCT03356613

Intervention type: OTHER
Intervention: Focus group
Description: An researcher in psychology will lead focus group on research views for paramedical staff

Intervention type: OTHER
Intervention: Focus group
Description: An researcher in psychology will lead focus group on research views for paramedical staff

Intervention type: OTHER
Intervention: Focus group
Description: An researcher in psychology will lead focus group on research views for paramedical staff

Intervention type: OTHER
Intervention: Focus group
Description: An researcher in psychology will lead focus group on research views for paramedical staff

Intervention type: OTHER
Intervention: test of the Geni tool
Description: The GenI tool built on paramedic's view will be tested.
Study: NCT01081886

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Electrosurgery with scalpel
Description: Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
Study: NCT01239784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based neurodevelopmental rehabilitation programme
Description: Participation in the study will require the parent and child to attend two assessment visits in addition to completing a series of parent and infant activities on a daily basis throughout the 10-week intervention period. The parent-led activities will include activities such as walking with the child, stacking blocks, rolling a ball to the child, hiding a toy under a blanket for the child to find, encouraging the child to kick a rattle while the child is lying on his/her back, or crawling or rolling in different directions.
Study: NCT00969683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Tracheal intubation using a Double lumen tube without a hook

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Description: Tracheal intubation with a Double lumen tube with a hook
Study: NCT02580747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-meso-CAR vector transduced T cells
Description: genetically engineered lymphocyte therapy
Study: NCT03438682

Intervention type: DEVICE
Intervention: Essure
Description: Essure hysteroscopic sterilization
Study: NCT01962246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin; Capecitabine
Description: Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxaliplatin; Capecitabine; concurrent radiotherapy
Description: Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT
Study: NCT03438682

Intervention type: PROCEDURE
Intervention: Laparoscopic sterilization
Description: Laparoscopic sterilization via electrocautery, ring, or clip.
Study: NCT01459393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA Photodynamic Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy with liquid nitrogen
Description: Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
Study: NCT02937636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous fluoride
Description: Experimental dentifrice containing 0.454% w/w stannous fluoride \& 0.0721% w/w sodium fluoride containing1450 parts per million (ppm) fluoride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: Dentifrice containing 0.14% w/w sodium monofluorophosphate containing1400 ppm fluoride
Study: NCT03438682

Intervention type: DEVICE
Intervention: Intrauterine Device (IUD)
Description: Intrauterine Device (IUD)